COMMUNIQUÉS West-GlobeNewswire

SK pharmteco participera au salon CPHI et présentera ses capacités de CDMO multimodales ainsi que son infrastructure mondiale de fabrication
21/08/2026
Les dirigeants et experts techniques de l’entreprise présenteront des solutions intégrées de bout en bout pour les petites molécules et les vecteurs viraux SK pharmteco est sponsor officiel du CPHI Sustainability Summit [...]
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
21/08/2026
MOUNTAIN VIEW, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
21/08/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following [...]
Synergy CHC Corp. Announces Receipt of Nasdaq Letter
21/08/2026
N. WINDHAM, Maine, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health and wellness company, today announced that it received a notice (the “Notice”) from [...]
Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)
21/08/2026
ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose Reduced Ventricular [...]
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
21/08/2026
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. [...]
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
21/08/2026
SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
21/08/2026
Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. [...]
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
21/08/2026
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced [...]
Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy
21/08/2026
ADELAIDE, Australia, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing international biotechs, today announced the appointment of Tim [...]
PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner
21/08/2026
U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel [...]
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care
21/08/2026
Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens 1 This immunotherapy doublet regimen demonstrated [...]
NICE Supports Routine NHS Funding and Access to Ex-Situ Machine Perfusion in a Major Step Forward for Liver Transplantation
21/08/2026
National Institute for Health and Care Excellence (NICE) guidance supports wider patient access to life-saving liver transplantation through routine adoption of machine perfusion technologies across England OXFORD, [...]
Bavarian Nordic Reports Strong First Half 2026 Results
21/08/2026
COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the second quarter and first half of 2026 and released its financial [...]
Bavarian Nordic to Launch New Share Buy-back Program of up to DKK 750 Million
21/08/2026
Repurchased shares will be subject to cancellation, pending shareholder resolution COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced its plans to launch a new share buy-back program [...]
Bavarian Nordic Upgrades its Full-Year 2026 Financial Guidance
21/08/2026
Guidance upgrade reflects upper end of previous guided revenue range and an improved EBITDA margin COPENHAGEN, Denmark, August 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an upgrade of the Company’s [...]
Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline
21/08/2026
PARIS, FRANCE, 21 AUGUST 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company adding late-stage MDM2 inhibitor [...]
Ipsen finalise l'acquisition de Kartos Therapeutics, renforçant son portefeuille d'oncologie en phase avancée
21/08/2026
PARIS, FRANCE, 21 AOUT 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) a annoncé aujourd’hui avoir finalisé l'acquisition de Kartos Therapeutics, une société biopharmaceutique au stade clinique, apportant le navtemadlin, un [...]
Aveanna Announces Pricing of Secondary Offering of Common Stock
21/08/2026
ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, [...]

Pages